Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 in extensive stage small cell lung cancer
NCT06052423Phase 2Withdrawn
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of risvutatug rezetecan in small cell lung cancer (SCLC), sponsored by Hansoh Pharmaceutical Group. Planned start Nov 2024; status: withdrawn.
02
Drugs
risvutatug rezetecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06052423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052423.